11 Marzo 2019

FDA Approves Atezolizumab Combo for Frontline TNBC

March 8, 2019 – The FDA has granted an accelerated approval to the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC). The approval is based on the phase III IMpassion130 trial, in which the addition of the PD-L1 inhibitor atezolizumab to nab-paclitaxel reduced the risk of progression or death by 40% compared with nab-paclitaxel … (leggi tutto)